Ronald Blue & Co’s Novartis NVS Stock Holding History

Ronald Blue & Co’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,260	Closed	-$217K	–	260
2017 Q1	$217K	Buy	+3,260	New	+$217K	0.01%	196
2016 Q1	–	Sell	-3,542	Closed	-$273K	–	217
2015 Q4	$273K	Sell	3,542 -13,015	-79%	-$1.03M	0.01%	136
2015 Q3	$1.36M	Sell	16,557 -2,618	-14%	-$233K	0.07%	57
2015 Q2	$1.69M	Sell	19,175 -2,828	-13%	-$259K	0.08%	47
2015 Q1	$1.94M	Buy	22,003 +281	+1%	+$24.9K	0.09%	41
2014 Q4	$1.8M	Buy	21,722 +355	+2%	+$29.4K	0.09%	52
2014 Q3	$1.8M	Buy	21,367 +1,001	+5%	+$81K	0.12%	42
2014 Q2	$1.65M	Buy	20,366 +778	+4%	+$61.2K	0.1%	49
2014 Q1	$1.49M	Buy	19,588 +1,585	+9%	+$115K	0.11%	48
2013 Q4	$1.3M	Sell	18,003 -1,326	-7%	-$92.2K	0.1%	65
2013 Q3	$1.33M	Buy	19,329 +17,777	+1,145%	+$1.18M	0.11%	50
2013 Q2	$98K	Buy	+1,552	New	+$101K	0.01%	164

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ronald Blue & Co's NVS Position: Q2 2017 in Review

Ronald Blue & Co sold out of Novartis (NVS) in Q2 2017, closing a stake of 3,260 shares — an estimated $217K sold.

Ronald Blue & Co first reported a position in NVS in Q2 2013 and held it in 12 quarters. The position peaked at $1.94M in Q1 2015. 921 funds tracked by Wall St. Rank hold NVS as of Q2 2017.

Ronald Blue & Co reported no remaining Novartis position as of Q2 2017 after selling out during the quarter.
Ronald Blue & Co sold 3,260 Novartis shares in Q2 2017, an estimated $217K.
Ronald Blue & Co first reported a position in Novartis in Q2 2013 and held it in 12 quarters.
Ronald Blue & Co's Novartis position peaked at $1.94M in Q1 2015.
921 funds tracked by Wall St. Rank held Novartis as of Q2 2017.

Based on Ronald Blue & Co's 13F filing for Q2 2017, filed 28 Jul 2017.